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Inherited platelet disorders are a heterogeneous group of rare diseases,caused by inherited defects in platelet production and/or function.Their genetic diagnosis would benefit clinical care, prognosis and pre-
ventative treatments. Until recently, this diagnosis has usually been per-
formed via Sanger sequencing of a limited number of candidate genes.
High-throughput sequencing is revolutionizing the genetic diagnosis of
diseases, including bleeding disorders. We have designed a novel high-
throughput sequencing platform to investigate the unknown molecular
pathology in a cohort of 82 patients with inherited platelet disorders.
Thirty-four (41.5%) patients presented with a phenotype strongly
indicative of a particular type of platelet disorder. The other patients had
clinical bleeding indicative of platelet dysfunction, but with no identifi-
able features. The high-throughput sequencing test enabled a molecular
diagnosis in 70% of these patients. This sensitivity increased to 90%
among patients suspected of having a defined platelet disorder. We
found 57 different candidate variants in 28 genes, of which 70% had not
previously been described. Following consensus guidelines, we qualified
68.4% and 26.3% of the candidate variants as being pathogenic and like-
ly pathogenic, respectively. In addition to establishing definitive diag-
noses of well-known inherited platelet disorders, high-throughput
sequencing also identified rarer disorders such as sitosterolemia, filamin
and actinin deficiencies, and G protein-coupled receptor defects. This
included disease-causing variants in DIAPH1 (n=2) and RASGRP2 (n=3).
Our study reinforces the feasibility of introducing high-throughput
sequencing technology into the mainstream laboratory for the genetic
diagnostic practice in inherited platelet disorders. 
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ABSTRACT
Introduction
Inherited platelet disorders (IPDs) are a heterogeneous
group of rare diseases of variable clinical severity, usually
characterized by mucocutaneous bleeding and excessive
blood loss after trauma or surgery. Some IPDs are due to
defects in genes that encode proteins that play critical
roles in megakaryopoiesis and proplatelet production,
leading to an inherited thrombocytopenia (IT).
Alternatively, the molecular pathology may affect the
development or maintenance of the platelet ultrastructure,
the formation and cargo of granules, or platelet responses
to agonists, which are known collectively as inherited
platelet function disorders (IPFDs). Not infrequently, IPDs
combine thrombocytopenia and impaired platelet func-
tion.1,2
Although phenotype-guided diagnosis is straightfor-
ward in some IPDs, including Bernard Soulier syndrome
(BSS), Glanzmann Thrombasthenia (GT) and Hermansky-
Pudlak syndrome (HPS), due to the severity of the bleed-
ing and a readily available flow cytometry test, or to the
syndromic nature of the disorder, most IPDs lack distinc-
tive clinical and laboratory features.  The diagnosis of this
group remains a challenge even under expert analysis.
Consequently, many IPDs remain underdiagnosed,
despite the many diagnostic algorithms that have been
proposed.3 Moreover, until recently, IPD diagnosis at the
genetic level has been attained in fewer than half of
patients, with the greatest success being seen in special-
ized centers.4,5 
Genetic diagnosis for IPD families would facilitate bet-
ter clinical care, prognosis and preventive treatments,
which are especially important for clinically severe IPDs,
or for those platelet syndromes that associate with an
increasing risk of malignancy, and which require genetic
counseling.6-8  While genotyping based on Sanger sequenc-
ing of candidate genes has been used successfully since the
early 1990s for some IPDs,4,5 the approach is, at present,
costly, time-consuming and not applicable to disorders
whose phenotype-based diagnosis is not straightforward
and for which there is no obvious candidate gene.6-8 The
recent advent of high-throughput sequencing (HTS),
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Table 1. Genes included in the HTS platform for molecular screening of IPDs.
Target protein Genes Chromosome location Genes Chromosome location
RBM8A 1q21.1 GFI1B 9q34.13
USF1 1q23.3 STIM1 11p15.4
Transcription Factors MPL 1p34.2 FLI1 11q24.3
HOXA11 7p15.2 RUNX1 21q22.12
CYCS 7p15.3 GATA1 Xp11.23
                                                                                               GP9                                            3q21.3                             P2RX1                                                    17p13.2
                                                                                            P2RY12                                         3q25.1                             GP1BA                                                   17p13.2
                                                                                             P2RY1                                          3q25.2                            ITGA2B                                                  17q21.31
Agonist platelet receptors                                              GP5                                             3q29                               ITGB3                                                   17q21.32
                                                                                             ITGA2                                          5q11.2                            TBXA2R                                                  19p13.3
                                                                                              CD36                                          7q21.11                              GP6                                                     19q13.42
                                                                                           ADRA2A                                       10q25.2                            GP1BB                                                  22q11.21
                                                                                               A2M                                          12p13.31                                                                                                  
LYST 1q42.3 HPS5 11p15.1
MLPH 2q37.3 ANO6 12q12
NBEAL2 3p21.31 VIPAS39 14q24.3
Platelet granules HPS3 3q24 BLOC1S6 15q21.1
AP3B1 5q14.1 MYO5A 15q21.2
DTNBP1 6p22.3 RAB27A 15q21.3
STX11 6q24.2 VPS33B 15q26.1
PRF1 10q22.1 UNC13D 17q25.1
PLAU 10q22.2 STXBP2 19p13.2
HPS1 10q24.2 BLOC1S3 19q13.32
HPS6 10q24.32 HPS4 22q12.1
                                                                                            ABCG5                                           2p21                             FERMT3                                                  11q13.1
                                                                                            ABCG8                                           2p21                               ACTN1                                                   14q24.1
Cytoskeletal assembly and                                          DIAPH1                                         5q31.3                             TUBB1                                                  20q13.32
structural proteins                                                       PRKACG                                       9q21.11                             MYH9                                                    22q12.3
                                                                                             ABCA1                                          9q31.1                               WAS                                                      Xp11.23
                                                                                          ANKRD26                                      10p12.1                             FLNA                                                       Xq28
                                                                                             MASTL                                        10p12.1                                                                                                   
GNAI3 1p13.3 PTGS1 9q33.2
PLA2G4 1q31.1 RASGRP2 11q13.1
Signal transduction RGS2 1q31.2 PTS 11q23.1
DHCR24 1p32.3 DPAGT1 11q23.3
TBXAS1 7q34 PLCB2 15q15.1
GNAQ 9q21.2 GNAS 20q13.32
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Table 2. General characteristics of 34 patients with a clinical and biological phenotype suggesting a particular type of IPD. 
Case Sex Age ISTH-BAT Consanguinity# Platelets Clinical symptoms, familial background, Suspected IPD
(x109/L) platelet phenotype
11. F 49 4 No 72 Lifelong macrothrombocytopenia MYH9-RD
with dominant inheritance
Deafness
12. F 1 1 No 20 Lifelong mild macrothrombocytopenia MYH9-RD
Neutrophil inclusion bodies in blood smear
13. M 11 1 No 90 Lifelong macrothrombocytopenia with dominant inheritance MYH9-RD
Neutrophil inclusion bodies in blood smear
14. M 37 3 No 50 Lifelong macrothrombocytopenia
Neutrophil inclusion bodies in blood smear MYH9-RD
15. F 27 3 No 30 Lifelong macrothrombocytopenia with dominant inheritance
Neutrophil inclusion bodies in blood smear MYH9-RD
16. F 26 2 No 87 Mild thrombocytopenia detected at pre-surgical screening
Deafness, mild renal disease MYH9-RD
17. F 48 3 No 30 Lifelong macrothrombocytopenia in several family members MYH9-RD
Sensorineural hearing loss in several family members
Neutrophil inclusion bodies in blood smear
18. F 11 0 No 88 Mild macrothrombocytopenia and neutropenia in several family members DIAPH1-RD
Sensorineural hearing loss in several family members 
No apparent neutrophil inclusion bodies in blood smear
Normal expression of major GPs. Normal platelet
aggregation and granule secretion to moderate
doses of several agonists
19. M 39 4 No 116 Mild macrothrombocytopenia and neutropenia in several family members DIAPH1-RD
Sensorineural hearing loss in several family members
No apparent neutrophil inclusion bodies in blood smear
Normal expression of major GPs
20. F 62 9 No 25 Lifelong macrothrombocytopenia BSS
Severely impaired platelet aggregation with ristocetin
Undetectable expression of GPIb/IX
21. F 4 2 No 89 Lifelong macrothrombocytopenia BSS
Severely impaired platelet aggregation with ristocetin
Normal platelet aggregation with other agonist
75% reduction in GPIb/IX platelet expression
2-fold increased expression of GPIIIa and GPIa
3 30% ristocetin-induced VWF binding
22. F 13 10 No 50 Lifelong macrothrombocytopenia BSS
<10% GPIbα expression
<10% ristocetin-induced VWF binding
23. M 62 12 No 4 Lifelong severe macrothrombocytopenia BSS
Absent GPIb/IX platelet expression
Mild increased expression of GPIIa, GPIa and GPVI
A Absent ristocetin-induced VWF binding
24. F 15 8 No 27 Lifelong macrothrombocytopenia GPS
Reduced agonist-induced P-selectin exposure
Decreased α-granules under electron microscopy
25. M 32 5 No 45 Lifelong macrothrombocytopenia GPS
Reduced number of α-granules under electron microscopy
26. F 21 1 No 36 Lifelong macrothrombocytopenia GPS
Normal or mild reduced platelet aggregation with several agonists
Marked impairment of agonist-induced P-selectin secretion
27. M 28 6 No 74 Lifelong macrothrombocytopenia GPS
Mildly reduced platelet aggregation with several agonists
Impaired agonist-induced P-selectin secretion
28. F 40 3 Yes 88 Lifelong macrothrombocytopenia STSL
Presence of stomatocytes in blood smear
Xanthelasma
continued on the next page
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29. M 1 2 No 35 Syndromic thrombocytopenia IT
Mental retardation, corpus callosum hypoplasia, DiGeorge
facial and cardiac abnormalities syndrome
30. F 46 10 No 84 Lifelong macrothrombocytopenia and absence of radii TAR
31. F 13 2 No 40 Lifelong thrombocytopenia with mildly increased platelet size FLNA-RD
Facial abnormalities and corpus callosum hypoplasia
32. F 42 5 No 59 Lifelong thrombocytopenia with normal platelet size RUNX1-RD
Family history of acute myeloid leukemia
Mildly reduced platelet aggregation with several agonists
Slightly prolonged PFA-100 closure times
33. M 4 4 No 87 Lifelong microthrombocytopenia WAS
Recurrent infections
Decreased WASP expression by flow cytometry GT
34. M 45 5 Yes 160 Severely impaired platelet aggregation with TRAP, ADP, 
epinephrine, arachidonic acid, and collagen.
50% reduced ristocetin-induced platelet aggregation
PFA-100 >300s; abnormal clot retraction
Undetectable GPIIb/IIIa platelet expression.
Normal expression of GPIb/IX, GPIa and GPVI
Absence of agonist-induced PAC-1 binding
35. F 27 10 Yes 175 Severely reduced platelet aggregation with several GT
agonists except ristocetin. Marked defect in GPIIb/IIIa expression.
Normal expression of GPIb/IX, GPIa and GPVI
36. M 7 6 Yes 220 Severely reduced platelet aggregation with several GT
agonists except ristocetin. Marked defect in GPIIb/IIIa expression.
Normal expression of GPIb/IX, GPIa and GPVI
37. F 8 5 Unknown 238 Severely impaired platelet aggregation with TRAP, ADP, GT
epinephrine, arachidonic acid and collagen.
50% reduced ristocetin-induced platelet aggregation
PFA-100 >300s; Abnormal clot retraction
Undetectable GPIIb/IIIa platelet expression
Normal expression of GPIb/IX, GPIa and GPVI
<20% agonist-induced fibrinogen binding
38. F 50 22 No 158 Severely impaired platelet aggregation with TRAP, ADP, 
epinephrine, arachidonic acid, and collagen.
Impaired ristocetin-induced platelet aggregation
PFA-100 >300s; Abnormal clot retraction
Undetectable GPIIb/IIIa platelet expression
Normal expression of GPIb/IX, GPIa and GPVI
Markedly impaired agonist-induced fibrinogen
Mildly impaired agonist-induced P-selectin and CD63 secretion GT
39. M 55 23 No 313 Severely impaired platelet aggregation with TRAP, ADP, 
epinephrine, arachidonic acid, and collagen. Normal ristocetin-induced GT
platelet aggregation  PFA-100 >300s; Abnormal clot retraction
85% reduction in GPIIb/IIIa platelet expression.
Normal expression of GP1b/IX, GPIa and GPVI
Markedly impaired agonist-induced fibrinogen binding
40. F 21 5 No 230 Reduced platelet aggregation with low dose collagen and CRP GPVI defect
Normal platelet aggregation with other agonists
Normal expression of GP IIb/IIIa, GPIb/IX and GPIa
50% expression of GPVI . Severely reduced CRP-induced fibrinogen binding and 
P-selectin secretion, but normal with other agonists
Similar platelet phenotype in mother
41. F 18 12 No 201 Albinism and granulomatous colitis
Mildly impaired platelet aggregation with low dose of ADP, HPS
epinephrine and ristocetin. Impaired serotonin uptake
Reduced number of dense granules under electron microscopy
continued on the next page
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either whole-genome sequencing (WGS), whole-exome
sequencing (WES), and targeted sequencing of pre-speci-
fied genes, has begun to revolutionize the field of genetic
diagnosis and is rapidly becoming established in clinical
practice.9,10 With respect to bleeding disorders, HTS is
emerging as a valuable tool for the molecular diagnosis of
hemophilia and other rare coagulation disorders, and also
for genotyping in IPDs.9,11 Thus, HTS is increasingly
important as the first-line of the diagnostic investigation
of these diseases.3,6,8,12,13
Herein, we report the design and implementation of a
multigenic HTS platform for genetic analysis of IPD
patients. The application of this novel approach has great-
ly aided our diagnostic process, resulting in a conclusive
molecular diagnosis in the largest series of IPD patients
investigated in the Iberian Peninsula. 
Methods
Patient enrollment, blood sampling, platelet 
phenotyping and DNA isolation
We studied 92 unrelated patients with suspected IPD, enrolled
prospectively within the aims of the multicenter “Functional and
Molecular Characterization of Patients with Inherited Platelet
Disorders” project, under the scientific sponsorship of the Spanish
Society of Thrombosis and Haemostasis. Patients with known
acquired disorders or clotting factor defects were excluded.
Investigations abided by the Declaration of Helsinki and were
approved by the Local Ethical Committees of the Instituto de
Investigación Biomédica (IBSAL, Salamanca, Spain) and Hospital
Universitario Reina Sofía (Murcia, Spain). All patients gave their
written informed consent. 
Clinical data of all patients were reviewed by the investigating
team and their bleeding symptoms were reassessed and scored
using the International Society on Thrombosis and Haemostasis
Bleeding Assessment Tool  (ISTH-BAT) questionnaire. Venous
blood samples were obtained for platelet phenotyping4 and
molecular studies (Online Supplementary Methods). 
Custom HTS panel design, sequencing and data 
analysis
Using Design Studio (Illumina, San Diego, CA, USA), we
designed a HTS platform with 1399 probes targeting 1106 regions,
including exons, untranslated regions (UTRs) and flanking regions,
of 72 genes that are associated with IPDs and/or are significant in
platelet physiology (Table 1).  Sequence data generated by HTS
was mapped to the Reference Human Genome (hg19) with MiSeq
integrated computer software (MiSeq Reporter, Illumina), which
uses a Burrows-Wheeler-Aligner (BWA) and Genome Analysis
Tool Kit (GATK) for variant-calling of single nucleotide variants
(SNVs) and short insertions/deletions (InDels).14,15 Secondary data
analysis, sequence alignment and variant detection was performed
with Variant Studio Data Analysis and Integrative Genomics
Viewer (IGV) (Broad Institute, Cambridge, MA, USA) software.
The coverage per base was ≥100 reads. The first step consisted of
a quality filter based on a Phred score  >20, Quality >20 and Read
coverage >30 at each position within the reads, to indicate high
sequence quality.  Data was then filtered according to the severity
of the consequence, in order to prioritize variants leading to an
amino acid change in the protein sequence (missense, nonsense,
frameshift) and those in the splice site and UTRs. Apart from
exceptional cases, synonymous and intronic variants were disre-
garded. Minor allelic frequencies (MAFs) were consulted in the
Exome Variant Server, 1000 Genomes Browser and exome aggre-
gation consortium (ExAC) databases; variants with a MAF 
of <0.05 were selected for further analysis. The other variants
were searched for across sources, such as the dbSNP147, the
Catalog of Somatic Mutations in Cancer (COSMIC), the National
Center for Biotechnology Information (NCBI) ClinVar, the HGMD
professional database, PubMed, Online Mendelian Inheritance in
Man (OMIM), and locus-specific mutation databases in an
attempt to identify variants known to cause IPDs (Online
Supplementary Figure S1).16 Several in silico tools, Polymorphism
Phenotyping v2 (PolyPhen-2), Sorting Intolerant From Tolerant
(SIFT), Mutation Taster, MutationAssessor and Functional
Analysis Through Hidden Markov Models (fathmm), were used
to predict the functional effects and pathogenicity of the novel
variants. We followed the guidelines of the American College of
J.M. Bastida et al.
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42. M 40 10 Yes 200 Prolonged PFA-100 closure times HPS
Albinism and pulmonary fibrosis
43. M 27 4 Unknown 312 Albinism and strabismus
Reduced serotonin uptake HPS
Impaired agonist-induced CD63 secretion
Reduced dense granules by electron microscopy
44. M 1 1 Unknown 180 Albinism CHS
Neutrophil inclusion bodies in blood smear
Impaired agonist-induced CD63 secretion.
Normal agonist-induced P-selectin release
#No information was provided regarding familiar consanguinity and no further investigations were carried out due to ethical reasons. MYH9-RD: MYH9 related disease; IT: inher-
ited thrombocytopenia; RUNX1-RD: RUNX1-related disease; GPS: Gray platelet syndrome; HPS: Hermansky-Pudlak syndrome; GT: Glanzmann thrombasthenia; BSS: Bernard
Soulier syndrome; FLNA-RD: filaminopathy or filamin-related disease; CHS: Chediak-Higashi syndrome; WAS: Wiskott-Aldrich syndrome; GPVI:  glycoprotein VI; STSL: sitos-
terolemia; TAR: thrombocytopenia with absent radius syndrome; WASP: Wiskott-Aldrich syndrome protein; TRAP: thrombin receptor activating peptide; ADP: adenosine diphos-
phate; CRP: collagen-related peptide; PFA: platelet function analyser; VWF: von Willebrand factor; GP: glycoprotein; IPD: inherited platelet disorder; ISTH-BAT: International Society
on Thrombosis and Haemostasis Bleeding Assessment Tool. 
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Medical Genetics and Genomics and Association for Molecular
Pathology,17 to qualify each identified variant as a “pathogenic
variant” (PV), “likely pathogenic variant” (LPV) or “variant of
uncertain significance”(VUS; Online Supplementary Figure S2).
For more methodological details, see the Online Supplementary
Methods.  
Results
Patient characteristics
Patients were divided into 2 groups (Figure 1): i) a small
validation group comprising 10 patients previously char-
acterized at the functional and molecular level,4,18 harbor-
ing known pathogenic variants identified by Sanger
sequencing (Online Supplementary Table S1), and ii) a larger
study group of 82 patients who were enrolled in the proj-
ect because of variable bleeding diathesis and abnormali-
ties in the number or function of platelets, or both, but
with unknown molecular pathology. Only 3 (3.7%) of
these patients had undergone Sanger sequencing of candi-
date genes, and this had failed to identify candidate dis-
ease-causing variants.
The major clinical and biological characteristics of the
82 patients in the study group are summarized in Table 2
and Table 3. The majority (62.2%) were female; median
age was 29 (1-82) years; median bleeding score was 5 (0-
23); median platelet count was 96 (4-617) x109/L. Fifty-
three cases (64.6%) presented with lifelong thrombocy-
topenia as the main inclusion criterion and the others had
laboratory abnormalities consistent with an IPFD. Forty
patients (50%) had a family history of bleeding, thrombo-
cytopenia and/or hematological malignancies. In 34 cases
(41.5%), clinical background and centralized laboratory
assessment supported the diagnosis of a particular type of
IT or IPFD:  MYH9 related disease (MYH9-RD), n=7;
DIAPH1 related disease (DIAPH1-RD), n=2;  BSS, n=4;
Gray platelet syndrome (GPS), n=4; sitosterolemia (STSL),
n=1; DiGeorge syndrome, n=1; thrombocytopenia with
absent radius syndrome (TAR), n=1; filaminopathy or fil-
amin-related disease (FLNA-RD), n=1; RUNX1-related dis-
ease (RUNX1-RD), n=1; Wiskott-Aldrich syndrome
(WAS), n=1; GT, n=6; glycoprotein VI (GPVI) signalling
defect, n=1; HPS, n=3; Chediak-Higashi syndrome
(CHS=1), n=1. The remaining 48 patients (58.5%) either
had low platelet counts (n=30) and/or platelet function
abnormalities (n=18) of uncertain etiology (Table 2 and
Table 3).
General performance of the HTS assay and validation
of the HTS multigenic platform
The 72 genes included in the panel (Table 1) were ana-
lyzed for all patients. We successfully sequenced 95.6% of
the 1106 target regions at a minimum coverage depth of
100 for each nucleotide base-pair position of interest. The
remaining 4.4% of regions could not be sequenced with
adequate coverage using the NGS platform (Online
Supplementary Table S2). In addition, the mean fraction of
exonic bases covered at 20X and 50X was 0.991 and 0.987,
respectively.
Genetic diagnosis of IPDs by HTS
haematologica | 2018; 103(1) 153
Figure 1. Classification of the 92 IPD patients sequenced with a novel HTS platform. Ninety-two unrelated patients with a suspicion of IPD were enrolled in the project
“Functional and Molecular Characterization of Patients with Inherited Platelet Disorders”. Patients fell into 2 main groups: on the left, a validation group comprising
10 IPD patients harboring known pathogenic variants identified by Sanger sequencing (Online Supplementary Table S1), and on the right, a study group of 82 IPD
patients with unknown molecular pathology. DNA from all patients was sequenced with an HTS platform targeting 72 genes (Table 1), as described in the Methods.
The identified genetic variants were prioritized and assessed for pathogenicity, as stated in the Methods. IPD: inherited platelet disorder; HTS: high-throughput
sequencing.
J.M. Bastida et al.
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Table 3. Clinical and biological characteristics of 48 patients with IPD of uncertain etiology. 
Case Sex Age ISTH-BAT Consanguinity# Platelets Clinical symptoms, familial background, Suspected
(x109/L) platelet phenotype IPD
45. F 53 2 No 138 Lifelong macrothrombocytopenia in several family members IT
Normal platelet GPs expression
Normal platelet aggregation
46. M 80 1 No 98 Lifelong macrothrombocytopenia in several family members IT
47. M 30 6 No 28 Lifelong macrothrombocytopenia in several family members IT
Severely reduced platelet aggregation with ristocetin.
Normal platelet aggregation with other agonists
50% reduction in GPIb/IX expression.
Increased expression of GPIIa and GPIa
50% reduced ristocetin-induced VWF binding
48. F 22 5 No 100 Lifelong macrothrombocytopenia in several family members IT
49. F 35 4 No 101 Lifelong macrothrombocytopenia in several family members IT
50. M 39 0 No 87 Lifelong macrothrombocytopenia in several family members IT
51. F 31 6 No 67 Lifelong macrothrombocytopenia in severalfamily members IT
52. F 14 2 No 85 Lifelong macrothrombocytopenia in several family members IT
53. F 21 2 No 70 Lifelong macrothrombocytopenia in several family members IT
54. F 22 5 No 123 Lifelong macrothrombocytopenia in several family members IT
55. M 74 2 No 69 Lifelong macrothrombocytopenia in several family members IT
56. F 16 2 No 80 Lifelong macrothrombocytopenia in several family members IT
57. F 4 4 No 115 Lifelong thrombocytopenia in several family members IT
58. F 15 3 No 94 Lifelong thrombocytopenia in several family members IT
Normal platelet size
59. F 53 13 No 139 Lifelong thrombocytopenia in several family members IT
60. M 37 0 No 35 Lifelong thrombocytopenia with dominant inheritance IT
61. F 43 11 No 135 Lifelong mild thrombocytopenia in several family members IT
Mildly reduced platelet aggregation with low dose ADP and epinephrine
62. F 54 13 No 140 Lifelong macrothrombocytopenia IT
Mildly reduced platelet aggregation with most agonists
63. F 40 7 No 99 Lifelong thrombocytopenia with slightly increased platelet size IT
Mildly reduced platelet aggregation with low dose ADP and epinephrine
64. F 43 1 No 60 Lifelong macrothrombocytopenia in the patient and her mother IT
Mildly reduced GPIb/IX expression
65. M 45 9 No 25 Lifelong thrombocytopenia in several family members IT
Reduced number of α-granules by electron microscopy
66. M 5 6 No 9 Lifelong macrothrombocytopenia IT
Lack of response to previous ITP treatments
67. M 56 4 No 50 Lifelong thrombocytopenia in several family members IT
Renal disease in the patient and his father
68. M 6 4 No 86 Lifelong thrombocytopenia IT
Mildly reduced platelet aggregation with ADP and TRAP
Reduced TRAP-induced P-selectin and CD63 expression
69. F 41 7 No 72 Lifelong thrombocytopenia with slightly increased platelet size IT
Significantly reduced platelet aggregation with epinephrine 
and mildly decreased with other agonist
Impaired PAR1-induced granule secretion
70. M 40 10 Unknown 65 Lifelong macrothrombocytopenia IT
Mitral regurgitation, Pericentral retinitis pigmentosa
Mental retardation
Impaired agonist-induced fibrinogen binding and P-selectin release
One sister also with thrombocytopenia and retinitis pigmentosa
continued on the next page
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71. F 72 22 Unknown 36 Lifelong thrombocytopenia IT
Relatives affected by hemophilia
Normal GPs expression
Slightly reduced platelet aggregation with several agonists
72. M 45 12 No 12 Lifelong thrombocytopenia in several family members IT
Normal platelet size, myelodysplasia
73. M 26 2 No 108 Lifelong thrombocytopenia, normal platelet volume IT
Reduced platelet aggregation with low dose of ADP, epinephrine, and collagen
Normal platelet GPs expression except GPIa (30%)
Normal agonist-induced platelet a P-selectin and CD63 secretion
74. M 16 5 Unknown 302 Mildly reduced platelet aggregation with ADP Platelet signaling/
and epinephrine secretion defect
75. F 82 9 No 12 Lifelong macrothrombocytopenia IT &
Normal expression of major GPs Platelet signaling/
Defective agonist-induced P-selectin and CD63 secretion  secretion defect
76. F 17 3 Yes 280 Reduced platelet aggregation with, ADP, epinephrine and low dose collagen
Normal platelet aggregation with other agonists PFA-100 >300s; 
Normal clot retraction
Normal expression of GPIIb/IIIa, GPIb/IX, and GPIa
Mildly reduced agonist-induced P-selectin, CD63 and serotonin release 
Impaired PAC-1 binding with ADP but normal with PMA
GPIIb/IIIa activation defect
77. F 21 6 No 215 Slightly reduced platelet aggregation with ADP and epinephrine Platelet signaling/
secretion defect
78. F 54 7 No 195 Slightly reduced platelet aggregation with ADP, Platelet signaling/
epinephrine and arachidonic acid secretion defect
79. F 55 10 No 315 Slightly reduced platelet aggregation with collagen, Platelet signaling/
ADP, and epinephrine secretion defect
80. F 66 9 No 220 Mildly reduced platelet aggregation with most agonists Platelet signaling/
secretion defect
81. M 36 5 No 198 Mildly reduced platelet aggregation with epinephrine and collagen Platelet signaling/
secretion defect
82. F 53 10 No 190 Mildly reduced platelet aggregation with ADP, and ristocetin Platelet signaling/
secretion defect
83. F 9 3 No 185 Mildly reduced platelet aggregation with ADP and ristocetin Platelet signaling/
secretion defect
84. F 36 8 No 226 Mildly reduced platelet aggregation with ADP and epinephrine Platelet signaling/
secretion defect
85. M 1 4 No 617 Mildly reduced platelet aggregation with ADP and epinephrine Platelet signaling/
secretion defect
86. F 13 3 No 182 Mildly reduced platelet aggregation with ADP and epinephrine Platelet signaling/
secretion defect
87. F 6 3 No 294 Slightly reduced platelet aggregation with ADP and epinephrine Platelet signaling/
secretion defect
88. F 4 2 Unknown 223 Mildly reduced platelet aggregation with most agonists Platelet signaling/
Normal expression of major platelet GPs secretion defect
Defective agonist-induced P-selectin, CD63 and serotonin release
89. F 39 14 No 267 Markedly reduced platelet aggregation with low dose ADP, Platelet signaling
collagen and CRP. Normal platelet aggregation with other agonists defect
Normal expression of GP IIb/IIIa, GPIb/IX, GPIa, and GPVI
Reduced agonist-induced fibrinogen binding with low ADP and CRP
Normal agonist induced P-selectin and serotonin secretion continued on the next page
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To validate the accuracy of our HTS platform for detect-
ing causative variants within these genes, we assayed, in a
blind manner, DNA from the 10 patients with previously
ascertained pathogenic variants by Sanger sequencing.
These included 12 SNV (9 missense variants and 3 non-
sense changes) and 1 deletion within 8 genes (Online
Supplementary Table S1).4,18 In each case the HTS test, and
accompanying data analysis, identified the previously
known genetic variant, thus demonstrating the high sensi-
tivity of the platform. Reproducibility studies were also
performed, in which 4 DNA samples from the validation
groups (Cases 1, 4, 8 and 10) were assayed in triplicate in
3 separate runs. After applying the prioritization protocol,
we found 100% concordance between runs in detecting
the correspondent variants present in each DNA, demon-
strating high intra-batch and inter-batch reproducibility of
the platform. 
General performance of the HTS multigenic platform in
the IPD study group 
The high sensitivity and reproducibility displayed by
our HTS platform in the validation group prompted us to
use it as the first genotyping method in the 82 patients of
the study group. As stated above, this included 34 (41.5%)
cases with a strong suspicion of a defined IPD, and 48
(58.5%) patients with phenotypes not suggestive of a par-
ticular type of IPD (Figure 1). 
Overall, by applying the bioinformatic tools described
in the Methods, there was a median of 169 (range: 128-
230) sequence variations across the 72 genes in the 82
patients. We prioritized 62 of these candidate variants in
56 (68.3%) index cases (Table 4 and Table 5). This includ-
ed 40 missense variants, 8 nonsense variants, 11
frameshift variants (deletion=11, Insertion-Deletion=1), 2
variants in the UTR region and 1 splice site variant within
29 genes. All these genetic changes were confirmed by
Sanger sequencing and segregated into available family
members. Variants were inherited in a homozygous/hem-
izygous manner in 14 patients, 4 cases were compound
heterozygous defects and the other 38 were heterozy-
gous. Forty-one (72%) variants had not been previously
reported in public databases and are therefore novel vari-
ants. Assessment of variant pathogenicity, following con-
sensus guidelines,17 led to 43 (69%) variants being classi-
fied as PV, 16 (26%) as LPV and 3 as VUS (5%) (Table 4
and Table 5). 
As expected, the HTS platform was highly sensitive in
detecting causal variants among patients with a strong
suspicion of defined IPDs. In 30 out of 34 (88.2%) of these
patients we identified 34 different candidate variants in 17
genes, which were identified in most cases as PVs (n=28),
but in 4 cases as LPVs and in 2 as VUS (Table 4). These
genetic findings gave rise to confirmation of diagnosis of
BSS (n=4), MYH9-RD (n=7), TAR (n=1), GPS (n=1), 
FLNA-RD (n=1), RUNX1-RD, (n=1), GT (n=5), HPS (n=3),
CHS (n=1), GPVI defect (n=1), and 2 rare cases of WAS
and STSL that we have recently reported in detail (Online
Supplementary Table S3). In 2 patients (Cases 18 and 19)
with macrothrombocytopenia, mild neutropenia and
familiar sensorineural hearing loss, the HTS identified the
p.Arg1213* variant in DIAPH1. In these families, the
p.Arg1213*  variant displayed full penetrance with deaf-
ness, minor impact on platelet functional status, and a
moderate effect on the platelet levels of DIAPH1 and
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90. M 9 7 Yes 315 Markedly reduced platelet aggregation with ADP, GPIIb/IIIa activation 
epinephrine and low-dose collagen defect43
Mildly reduced aggregation with other agonists
PFA-100 >300s; normal clot retraction
Normal expression of GPIIb/IIIa, GPIb/IX, GPIa and GPVI
Severely reduced fibrinogen binding with all agonists but PMA
91. M 8 7 Unknown 193 Markedly reduced platelet aggregation with ADP, epinephrine, GPIIb/IIIa activation
low-dose collagen and CRP defect
Mildly reduced aggregation with other agonists
PFA-100 >300s; normal clot retraction
Normal expression of GPIIb/IIIa, GPIb/IX, GPIa and GPVI
Reduced fibrinogen binding with all agonists but PMA
Mildly reduced platelet secretion
92. F 4 9 NO 309 Markedly reduced platelet aggregation with all agonists GPIIb/IIIa activation
PFA-100 >300s; normal clot retraction defect
Normal expression of GPIIb/IIIa, GPIb/IX, GPIa and GPVI
Reduced fibrinogen binding with all agonists but PMA
Mildly reduced platelet secretion
#No information was provided regarding familiar consanguinity and no further investigations were carried out due to ethical reasons. IT: inherited thrombocytopenia; WAS:
Wiskott-Aldrich syndrome; GPVI:  glycoprotein VI; TRAP: thrombin receptor activating peptide; ADP: adenosine diphosphate; CRP: collagen-related peptide; PFA: platelet function
analyser; VWF: von Willebrand factor; GP: glycoprotein; IPD: inherited platelet disorder; ISTH-BAT: International Society on Thrombosis and Haemostasis Bleeding Assessment
Tool; ITP: Idiopathic Thrombocytopenic Purpura; PMA: phorbol 12-myristate 13-acetate.
continued from the previous page
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Tubulin β1 (Online Supplementary Figure S3, S4, S5 and S6).
Moreover, HTS failed to identify PV and LPV variants in 1
patient with what was previously thought to be a straight-
forward diagnosis of GT (Case 34) and in 3 cases with a
suspicion of GPS (Cases 24-27; Table 2). Furthermore, in
Case 27, who had suspected GPS, we found 2 novel mis-
sense variants in STIM1 and RUNX1 (Table 4). These vari-
ants, similarly to that of a variant in GNAS in Case 86
(Table 5), were classified as VUS on the basis of their iden-
tification only in the index case, since no relatives were
available for screening, there are no previous reports in
other patients, and no specific studies demonstrating a
deleterious functional effect.17
The overall sensitivity of the HTS platform was signifi-
cantly lower (Z-score=3.0599; P=0.00222) among the sub-
group of IPD of uncertain etiology. Herein, we identified
26 different variants located in 16 genes in 26 cases
(54.2%).  Most of them were classified as PV or LPVs (12
and 13, respectively) and one was identified as VUS.
Accordingly, these patients were assigned a diagnosis of
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Table 4. Genetic variants identified with the HTS test in patients with suspicion of particular IPDs according to their clinical and biological phe-
notype.
Case Gene Status cDNA mutation Protein change Reference MAF MAF Variant
ExAC 1000 Genome assessment*
11 MYH9 Het c.2707C>G p.Arg903Gly Novel No data No data Pathogenic
12 MYH9 Het c.220A>G p.Lys74Glu Novel No data No data Pathogenic
13 MYH9 Het c.4250G>A p.Arg1417Gln Novel No data No data Pathogenic
14 MYH9 Het c.5773delG p.Asp1925Thr fs*23 33 No data No data Pathogenic
15 MYH9 Het c.5797C>T p.Arg1933* 33 No data No data Pathogenic
16 MYH9 Het c.287C>T p.Ser96Leu 33 No data No data Pathogenic
17 MYH9 Het c.3486G>T p.Arg1162Ser Novel No data No data Pathogenic
18 DIAPH1 Het c.3637C>T p.Arg1213* 34 No data No data Pathogenic
19 DIAPH1 Het c.3637C>T p.Arg1213* 34 No data No data Pathogenic
20 GP1BA Hom c.673T>A p.Cys225Ser 4,26 No data No data Pathogenic
21 GP1BA Hom c.463C>G p.Leu155Val Novel No data No data Pathogenic
22 GP1BB Hom c.80C>T p.Pro27Leu Novel No data No data Pathogenic
23 GP1BB C. Het c.443G>A p.Trp148* Novel No data No data Both pathogenic
c.500T>C p.Leu167Pro Novel
24 NBEAL2 Hom c.6212G>C p.Arg2071Pro 48 No data No data Pathogenic
27 STIM1 Het c.563A>G p.Gln188Arg Novel No data No data Both uncertain
RUNX1 Het c.596G>C p.Gly199Ala Novel No data No data significance
28 ABCG5 C. Het c.1890delT p.Phe630Leu fs*8 36 No data No data Pathogenic
c.914C>G p.Thr305Arg 0.000015 0,00004143 Likely pathogenic
30 RBM8A Hom c.-21G>A - 22 0,034 0,056 Pathogenic#
(+deletion 1q21.1) - - -
31 FLNA Het c.3695C>T p.Thr1232Ile Novel No data No data Likely pathogenic
32 RUNX1 Het c.476A>G p.Asn159Ser Novel No data No data Likely pathogenic
33 WAS Hem c.449+5G>A --- 49 No data No data Pathogenic
35 ITGA2B Hom c.2333A>C p.Gln778Pro 50 No data No data Pathogenic
36 ITGA2B Hom c.2063C>T p.Ala688Val Novel 0 0 Pathogenic
37 ITGA2B C. Het c.2965delG p.Ala989Pro fs*142 Novel No data No data Both Pathogenic
c.2944G>A p.Val982Met 51
38 ITGA2B Hom c.2965delG p.Ala989Pro fs*142 Novel No data No data Pathogenic
39 ITGB3 Hom c.431T>G p.Met144Arg 52 No data No data Pathogenic
40 GP6 Het c.708_711delCGAA p.Asn236Lys fs*105 Novel 0.000083 No data Pathogenic
41 HPS4 Hom c.2054delC p.Pro685Leu fs*17 53 No data No data Pathogenic
42 HPS4 Hom c.272T>C p.Leu91Pro Novel No data No data Pathogenic
43 HPS3 Het c.2464C>T p.Arg822* Novel No data No data Likely pathogenic
44 LYST C. Het c.10100delA p.Lys3367Arg fs*34 All Novel No data No data All Pathogenic
c.10095G>C p.Lys3365Asn
c.7136T>C p.Leu2379Pro
*Pathogenicity assessment was assessed following the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.17
#Pathogenic in combination with deletion of 1q21.1.22 MAF: minor allele frequency; cDNA: complementary DNA; ExAC: The Exome Aggregation Consortium. 
monoallelic BSS (n=5); tubulin β1-related thrombocytope-
nia (TUBB1-RT), n=5; RUNX1-RD, n=2; actinin-1 related
thrombocytopenia (ACTN1-RT), n=1; type-2 thrombocy-
topenia (ANKRD26-RT), n=1; WAS, n=1. The other cases
presumably had congenital defects in the gene encoding
for ADP receptor P2Y12 (P2RY12)(n=1); thromboxane A2
receptor gene (TBXA2R) (n=1); Ca2+ DAG-regulated gua-
nine nucleotide exchange factor I or CalDAG-GEFI (RAS-
GRP2) (n=3) (Online Supplementary Table S3); G-protein α
subunit or Gs-α (GNAS) (n=1); phospholipase β2 (PLCB2)
(n=1); prostaglandin-endoperoxide synthase 1 (PTGS1)
(n=2); thromboxane A synthase 1 (TBXAS1) (n=1); and
integrin α2 (ITGA2)(n=1); (Table 5). 
Discussion
In recent years, the identification of the underlying
molecular pathology has become the cornerstone for estab-
lishing a conclusive diagnosis of IPDs, leading to better clin-
ical care and follow-up of these patients.6,7 Until recently,
Sanger sequencing of candidate genes and linkage studies
have been the main tools for IPD genetic diagnosis, provid-
ing outstanding but limited results.4,5 In 2010, HTS emerged
as the herald of the revolution in genetic diagnosis of
human diseases, including IPDs.6-8,13
The study herein demonstrates the feasibility of an in-
house designed HTS platform for rapid genetic characteri-
zation of patients with IPDs in a clinical setting. Indeed,
60% of patients in our study had no diagnostic features
allowing for a straightforward selection of candidate genes
and the use of Sanger sequencing. Further, for those
patients who presented with a phenotype indicative of a
particular type of disorder, most were associated with dis-
eases that can be due to defects in several genes and/or in
large genes, thus hampering Sanger sequencing (Table 4).
We have already used a detailed phenotyping and Sanger
sequencing approach for this group of IPD patients,4 and it
compares negatively with our current HTS test both in
terms of time and cost, although we did not undertake a
full cost-benefit analysis.
The current version of this platform allows for multiplex
analysis of coding and selected non-coding regions of 72
genes including those previously associated with IPDs
(Table 1). However, it can be easily modified to include
additional genes such as those recently identified: SLFN14,
ETV6, and SCR.2,6,13 None of the patients in this IPD study
had phenotypes consistent with these genes, but they are
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Table 5. Genetic variants identified with the HTS test in the cohort of patients with IPDs of uncertain etiology on the basis of clinical and biological
phenotype.
Case Gene Status cDNA mutation Protein change Reference MAF MAF Variant 
ExAC 1000 Genome assessment*
45 GP1BA Het c.463C>G p.Leu155Val Novel No data No data Pathogenic
46 GP1BA Het c.673T>A p.Cys225Ser 4,26 No data No data Pathogenic
47 GP1BA Het c.1474delA p.Thr494Pro fs*59 Novel No data No data Likely pathogenic
48 GP1BB Het c.119G>A p.Gly40Glu Novel 0,0044 0,0047 Likely pathogenic
49 GP1BB Het c.1A>T p.Met1Leu 31 No data No data Likely pathogenic
51 TUBB1 Het c.1075C>T p.Arg359Trp Novel No data No data Pathogenic
52 TUBB1 Het c.319A>C p.Thr107Pro Novel No data No data Likely Pathogenic
53 TUBB1 Het c.319A>C p.Thr107Pro Novel No data No data Likely Pathogenic
54 TUBB1 Het c.1267C>T p.Gln423* Novel No data No data Pathogenic
55 TUBB1 Het c.35delG p.Cys12Leu fs*12 Novel No data No data Pathogenic
64 ACTN1 Het c.137G>A p.Arg46Gln 54 No data No data Pathogenic
66 WAS Hem c.802delC p.Arg268Gly fs*40 32 No data No data Pathogenic
72 ANKRD26 Het c.-118C>T - 38 No data No data Pathogenic
73 RUNX1 Het c.802C>T p.Gln268* Novel No data No data Likely pathogenic
74 RUNX1 Het c.1205C>T p.Ser402Phe Novel 0 0 Likely pathogenic
77 P2RY12 Het c.835G>A p.Val279Met Novel No data No data Likely pathogenic
78 TBXA2R Het c.620C>T p.Ser207Leu Novel No data No data Likely pathogenic
79 ITGA2 Het c.3472T>C p.Phe1158Leu Novel No data No data Likely pathogenic
82 TBXAS1 Het c.1181C>T p.Thr394Ile Novel No data No data Likely pathogenic
84 PTGS1 Het c.35_40delTCCTGC p.Leu13_Leu14del Novel No data No data Likely pathogenic
86 PTGS1 Het c.428A>G p.Asn143Ser Novel No data No data Likely pathogenic
87 GNAS Het c.1276G>C p.Ala462Pro Novel No data No data Uncertain significance
89 PLCB2 Het c.1303G>A p.Phe435Lys Novel 0 No data Likely pathogenic
90 RASGRP2 Hom c.1142C>T p.Ser381Phe 43 No data No data Pathogenic
91 RASGRP2 Hom c.706C>T p.Gln236* Novel No data No data Pathogenic
92 RASGRP2 Hom c.887G>A p.Cys296Tyr Novel No data No data Pathogenic
*Pathogenicity assessment was performed following the guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.17
MAF: minor allele frequency; cDNA: complementary DNA; ExAC: The Exome Aggregation Consortium. 
of interest for novel cases referred to our project.  The
ThromboGenomics platform does not currently include
these genes, but patients with gain-of-function variants in
SCR have been reported.19 
We first performed a validation study of previously ascer-
tained genetic variants in blinded samples, which con-
firmed the strong analytical sensitivity and reproducibility
of the HTS platform, and the appropriateness of our vari-
ant-filtering strategy. We detected the 13 known variants in
eight genes, including missense and nonsense variants and
small deletions, from 10 patients (Online Supplementary
Table S1).  
Subsequently, we used the HTS multigenic platform for
the first genetic analysis of a cohort of 82 patients prospec-
tively enrolled from different hospitals in order to realize
the aim of the collaborative project “Functional and
Molecular Characterization of Patients with Inherited
Platelet Disorders”. The clinical and platelet phenotypic
presentation was highly variable among these patients,
which is consistent with the widely recognized hetero-
geneity of IPDs. Most patients (65%) presented with
thrombocytopenia as their main hematological feature.
Many of them also displayed a variable degree of platelet
dysfunction consistent with recent findings in other IT
series.20 Not surprisingly, the majority of patients were
women (62.2%), as more frequent bleeding complications
in females facilitate their clinical identification. Moreover,
most individuals (67%) were adults (aged >18 years) at the
time of our centralized phenotypic evaluation and selection
for molecular analysis. We have previously shown that, at
least in our clinical setting, there is a significant delay
between the time patients are suspected to have an IPD
and the time confirmatory phenotypic diagnosis and
molecular characterization are performed.4 The significance
of this should not be underestimated, as it implies that
many patients remain without a conclusive diagnosis for
years, and thus are at risk of receiving inappropriate treat-
ments. Multicentre collaboration, as supported by our proj-
ect, and availability of HTS are expected to change this. 
Overall, our HTS approach enabled a molecular diagno-
sis in 68.3% of the patients (Figure 1), which is a much
higher success rate than we achieved using only candidate
gene sequencing.4 Remarkably, this sensitivity increased to
nearly 90% for patients presenting with a well-defined clin-
ical and laboratory phenotype indicative of a particular
type of IPD. These results resemble those recently reported
for the ThromboGenomics HTS platform, which covers
the molecular screening of 63 genes.11 However, among
patients presenting with an unclear phenotype other than
bleeding or low platelet count, i.e., IPDs of uncertain etiol-
ogy, our HTS platform was only able to identify candidate
variants in about 50% of patients. This value is higher than
that reported by the ThromboGenomics consortium in the
same category of patients,11 but similar to the sensitivity
recently achieved by WES in a limited cohort of IT patients
with unknown etiology.20 Several factors could potentially
contribute to this difference. Our study recruited only
patients with established IPDs, even though the etiology of
about half of them could not be inferred from clinical and
laboratory data. In contrast, the ThromboGenomics study
enrolled, among “cases with a highly uncertain etiology”,
patients with bleeding problems but normal platelet func-
tion tests, and a few patients who had experienced throm-
botic events. In addition, the gene content in both plat-
forms is different, with only 33 genes from our platform
(Table 1) being present in the ThromboGenomics platform,
which also included genes involved in coagulation disor-
ders.11 
The failure to identify candidate genetic defects in about
30% of cases may be due to intrinsic limitations of our HTS
platform. First, the causative gene may not be present in
the panel. Second, HTS methods can miss large deletions or
duplications (>200bp), copy number variants involving
>1000bp, or big structural chromosomal variants, translo-
cations and aneuploidy, unless they have been specifically
designed for such a purpose.21 Thus, for successful molecu-
lar diagnosis of certain cases, the HTS test must be com-
bined with other molecular approaches such as compara-
tive genomic hybridization (CGH) array, quantitative poly-
merase chain reaction (q-PCR), or multiplex ligation-depen-
dent probe amplification  (MLPA).  For instance, in Case 30,
who was diagnosed with TAR, the HTS test detected the
uncommon rs139428292 single nucleotide polymorphism
(SNP), inherited from the father (Online Supplementary
Figure S7), but was insensitive to the pathogenic microdele-
tion in 1q21.1 which is associated with the disorder,22 and
which was later detected by CGH-array analysis (Online
Supplementary Figure S7). Standard analysis of HTS results
also failed to identify candidate variants in Case 29, who
had a clinical suspicion of DiGeorge syndrome (Table 2).
However, massive parallel sequencing of CNVs analysis by
HTS identified a RUNX1 deletion (Online Supplementary
Figure S8), and hybridization in situ analysis revealed a
21q22 microdeletion (data not shown), resulting in RUNX1
haploinsufficiency.23 Moreover, our HTS platform also left a
few target regions with insufficient coverage (<20x). This
affected up to 21 genes, although none of them appeared to
be related to the phenotypes of the corresponding patients
(Online Supplementary Table S2). In Case 34, who had an
unambiguous phenotype of GT but no HTS findings, no β3
messenger ribonucleic acid (mRNA) was detected, but
Sanger sequencing of the candidate ITGB3 in the patient
DNA also yielded negative results. It has been suggested
that the few GT patients in whom no ITGA2B and ITGB3
variants are detected might benefit from whole genome
analysis. This may unravel defects in regulatory elements
and deep intronic regions that adversely affect the tran-
scription or post-translational modifications and trafficking
of αIIbβ3 integrin.24 In addition, for most IPDs of uncertain
etiology and in a few suspected ones, such as our Cases 25-
27 who had a suspicion of GPS, the lack of genetic variants
in our study highlights that many genes which cause IPDs
or pathogenic variants affecting noncoding regulatory
regions of the genome remain unidentified. Large-scale
HTS projects, such as the 100,000 Genomes project in the
UK and other novel approaches to gene discovery6,7 will
help to overcome this limitation.
In this series of patients, we found 57 different candidate
variants in 28 genes, 70% of which were absent from the
main reference databases, thus emphasizing the great het-
erogeneity of the molecular pathology underlying IPDs.
Appropriate interpretation of the pathogenicity of candi-
date genetic variants found by HTS in IPDs remains a
major challenge, especially for novel variants, even if pres-
ent in well-established IPD genes. To prevent misinterpre-
tation, the use of consensus guidelines is highly recom-
mended,13,17 although there remains significant discordance
between laboratories.25 Herein, following established
guidelines,17 we classified 68.4% and 26.3% of the identi-
fied candidate variants as PV and LPV, respectively. In 2
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cases (27 and 87) we found 3 (5.2%) novel variants affect-
ing STIM1, RUNX1 and GNAS which qualified as VUS.
Lack of segregation of novel candidate variants in the pedi-
grees is critical to prevent over-interpretation of patho-
genicity. As an example, we disregarded novel variants in
GP1BA (Case 45, c.1022C>G, p.Ser341Cys), FLNA (Case
63, c.5933 C>T, p.Thr1978Met), MASTL (Case 58,
(c.836C>G; p.Pro279Arg) and NBEAL2 (Case 70,
c.3424G>T, p.Gly1142Cys), since they were present in
family members exhibiting no platelet defects.
The genetic findings of this study are of clinical and sci-
entific relevance. We established a conclusive diagnosis of
autosomal recessive severe IPDs or X-linked disorders in
about 25% of the patients, which would have informed
decisions regarding their clinical care. These included diag-
nosis of BSS (n=4), GT (n=6), HPS (n=3), CHS (n=1), GPS
(n=1), TAR (n=1) and WAS (n=2). One BSS patient carried
a missense p.Cys225Ser variant in GP1BA, which has been
previously identified in other patients from the Iberian
peninsula, thereby  suggesting a common ancestry.4,26
Another patient carried the novel change p.Leu155Val, also
in GP1BA, which resembles the previously reported
Bolzano variant p.Ala156Val, as it associates with severe
biallelic BSS and nearly asymptomatic monoallelic BSS.26 It
is worth mentioning that heterozygous variants in the
GP1BA and GP1BB genes were a common cause of domi-
nant IT in our series of patients, lending further weight to
the idea that this condition might be more common than
previously recognized.26,27 Six GT patients were diagnosed
in this study. HTS revealed no pathogenic variants in
ITGA2B and ITGB3 in 1 of these (Case 34), although the
patient presented with an obvious type I GT platelet phe-
notype and no detectable levels of ITGB3mRNA by quan-
titative real-time (qRT)-PCR. This case, along with those
few GT patients previously reported to have no detectable
mutations in ITGA2B and ITGB3,24,28 might benefit from
whole-genome analysis with the aim of identifying defects
in regulatory elements and deep intronic regions that
adversely affect the transcription or post-translational mod-
ifications and trafficking of αIIbβ3. HTS cannot fully
replace clinical evaluation and platelet phenotyping as it
may result in misdiagnosis, but molecular characterization
should be a component of an integral protocol for diagno-
sis. A similar argument may be valid for the 3 patients pre-
senting with a phenotype suggestive of GPS (Cases 25-27),
in whom we found no candidate variants in NBEAL or
GFI1B. This is in accordance with multiple unknown geno-
typic alterations that may underlie the GPS phenotype. The
clinical value of patient care and an accessible HTS test is
also well exemplified in the case of severe multi-system
IPDs such as HPS (Cases 41-43), CHS (Case 44) and WAS
(Cases 33 and 66), in which the gene affected, as in the
cases of HPS, or the type of mutation, regarding CHS and
WAS, is likely to predict phenotype.29-31 Early identification
of patients with these potentially life-threatening IPDs,
depending on the genotype, is critical to the successful
application of hematopoietic stem cell transplantation, and
possibly gene therapy in some cases. Remarkably, in this
project 3 young children had their molecular diagnosis con-
firmed as having either CHS or WAS defects, and 1 of the
WAS patients (Case 66) atypically presented with
macrothrombocytopenia of uncertain phenotype.32 
The importance of genotype in predicting a patient´s
clinical phenotype is also apparent in MYH9-RD.33  Herein,
our HTS platform identified 7 pathogenic variants in
MYH9 in 7 unrelated cases.  Three were unreported vari-
ants affecting the head domain of the protein, the
SH3/MDi region, and another novel variant affected the tail
domain. Notably, 5 of these patients were young individu-
als (<30 years old) who presented with no extra-hemato-
logical manifestations, and who could therefore benefit
from close follow-up.  
Two notable pedigrees, Cases 18 and 19, were originally
referred to us with a clinical suspicion MYH9-RD on the
basis of mild macrothrombocytopenia and autosomal
dominant sensorineural hearing loss. Subsequent analysis
of the clinical and biological records in all relatives affected
by deafness showed variable thrombocytopenia, absence
of inclusion bodies in neutrophils and mild neutropenia.
These data did not support the suspicion of MYH9-RD, but
prompted us to suspect an underlying molecular pathology
in DIAPH1. In OMIM this gene is usually linked to autoso-
mal dominant deafness with/without thrombocytopenia,
and thus is considered to be a phenocopy of MYH9.
Remarkably, our HTS test revealed, in both pedigrees, the
variant p.Arg1213* in DIAPH1, with full penetrance and
with deafness presenting as the main clinical abnormality.
This is a gain-of-function variant affecting autoregulation
of DIAPH1 activity and proplatelet formation, recently
identified by the ThromboGenomics consortium in 2 unre-
lated pedigrees with a similar phenotype to that in our
cases.34 Functional studies of our patients revealed a minor
effect of the p.Arg1213* variant in platelet aggregation and
secretion, while it associates with a mildly reduced platelet
expression of the DIAPH1 protein and a slightly higher
level of tubulin β1 (Online Supplementary Material). Our cur-
rent data generally concord with the previously reported
phenotype in p.Arg1213* carriers,34 and gives further sup-
port to the idea that DIAPH1-RD is a novel type of IPD.
Few other rare cases were identified with a novel molec-
ular pathology affecting genes encoding cytoskeletal pro-
teins involved in proplatelet formation, such as TUBB1
(Cases 51-55), ACTN1 (Case 64) and FLNA (Case 31).2 The
later patient, a 13-year-old girl who displayed moderate to
severe thrombocytopenia, had required sporadic blood
transfusions and had been investigated for suspicion of
WAS and CAMT, despite some clinical signs suggesting a
filaminopathy (Table 2). Our identification of the novel
missense mutation (c.3695C>T; p.Thr1232Ile) in exon 22 of
FLNA supported the diagnosis of filaminopathy and war-
rants  a more specific clinical investigation. This novel
FLNA variant appears to be a de novo variant in the patient
(Online Supplementary Figure S9), a phenomenon that occurs
in about 20-30% of cases with sporadic bilateral periven-
tricular nodular heterotopias.35 Additionally, 1 patient (Case
28) was characterized with STSL, a rare inherited sterol
storage disorder.36 Functional in vitro studies are underway
to explore the potential deleterious effect of these variants
in platelet formation.
Three novel variants in RUNX1 were found in Cases 32,
73 and 74, who all presented with mild platelet dysfunc-
tion, whilst 2 of them also had thrombocytopenia. Only
members of 1 of these families had a history of hematolog-
ical malignancy. These variants are expected to affect the
function of RUNX1, as 2 (p.Gln268* and p.Asn159Ser) lie
within the RUNT homology domain which mediates DNA
binding and heterodimerization with CBFβ and the
remaining (p.Ser402Phe) in the C-terminal inhibitory
domain of RUNX1.37 Comprehensive interpretation of vari-
ants in this transcription factor, like those in ANKRD26
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(Case 72 in our series), is relevant as such variants may
increase the risk of developing myeloid malignancies.37,38
In Case 40, the selective platelet dysfunction at the GPVI
level, which likely had autosomal dominant inheritance,
matched well with the finding of a novel in-frame deletion
in GP6 detected by HTS. Among the subgroup of patients
presenting with mild platelet dysfunction of uncertain eti-
ology, 8 (44%) pedigrees exhibited likely pathogenic het-
erozygous variants in genes encoding other platelet recep-
tors (ITGA2, TBXA2R, P2YR12) or enzymes involved in
second messenger release and platelet signal transduction
(GNAS, PLCB2, PTGS1, TBXAS1; Table 5). Further studies
are required to determine the contribution, if any, of these
genetic defects to the platelet dysfunction and bleeding ten-
dency of these patients. Interestingly, other patients previ-
ously reported to have inherited defects in these platelet
proteins were also heterozygous.39,40 Bleeding diathesis in
these patients may be facilitated by co-inheritance with
other genetic disorders of hemostasis, such as type 1 von
Willebrand disease.41
A key protein for integrin signaling in platelets and neu-
trophils is the guanine nucleotide exchange factor
CalDAG-GEFI. Recently a variant in RASGRP2, the gene
encoding CalDAG-GEFI, was identified in 3 siblings with
impaired platelet function and bleeding diathesis.42 Herein,
our HTS test identified 3 novel variants in RASGRP2
(p.Ser381Phe, p. Gln236* and p. Cys296Tyr) from 3 unre-
lated children with lifelong severe bleeding complications
and reduced platelet aggregation with most agonists.
Further functional studies demonstrated that these novel
variants severely affect CalDAG-GEFI expression and
activity, leading to defective agonist-induced integrin acti-
vation in platelets and neutrophils.43,44 Of late other patients
harboring pathogenic variants in RASGRP2 have been iden-
tified,45-47 indicating that this type of IPFD might occur more
frequently than previously thought. 
Conclusions
This study demonstrates that our HTS platform is an
accurate, reproducible and reliable tool for the genetic char-
acterization of IPDs. Using this approach, we can achieve a
molecular diagnosis in most patients with a suspected eti-
ology, and in about half the cases presenting with a disease
of highly uncertain biological cause. Our findings reinforce
the feasibility of introducing this technology into main-
stream genetic testing for diagnosing IPDs. Patients with an
IPD in which the HTS platform fails to identify the under-
lying molecular pathology are candidates for examination
using less restrictive molecular approaches, such as WES or
WGS. The use of human phenotype ontology codification,
consensus guidelines for interpreting genetic variants, and
in silico bioinformatics analysis tools to facilitate the identi-
fication of candidate causative variants will be important in
aiding this process. However, definitive pathogenicity
assignment of novel rare variants must be established on
the basis of their identification in unrelated pedigrees with
similar phenotype and/or demonstrative functional studies. 
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